What Is Casodex and What Is It Used For?

Casodex is the brand name for bicalutamide, a prescription medication that blocks the effects of male sex hormones (androgens) on the body. It was developed specifically to treat prostate cancer, which in most cases depends on testosterone and related androgens to grow and spread. Bicalutamide belongs to a class called non-steroidal antiandrogens, and its most common role is as a partner drug alongside other hormone therapies that lower testosterone levels. The story of how it fits into prostate cancer treatment, its side effects, how it stacks up against newer drugs, and a growing list of off-label uses is more layered than the label alone suggests.

How Bicalutamide Works

Prostate cancer cells have androgen receptors on their surfaces that act like locks. Testosterone and its more potent form, dihydrotestosterone, are the keys. When these hormones attach to the receptor, they trigger the cell to grow and divide. Bicalutamide works by sitting in the receptor’s hormone-binding pocket without activating it, effectively jamming the lock so the real keys cannot turn it. Structural studies show that the drug distorts part of the receptor called helix 12, which in turn prevents helper proteins (coactivators) from docking and switching on the genes that drive cancer growth.¹

Because bicalutamide blocks the receptor rather than lowering testosterone production, testosterone levels in the blood actually stay the same or even rise slightly while you take it. That distinction matters for side effects and for how the drug is combined with other treatments.

The Standard Use in Combined Androgen Blockade

The most common way bicalutamide is prescribed is at a dose of 50 mg once daily, taken alongside a drug that suppresses testosterone production. These testosterone-lowering drugs, called LHRH agonists (leuprolide is one well-known example), work by shutting down the hormonal signals from the brain that tell the testes to make testosterone. The pairing of both approaches is known as combined androgen blockade, or CAB. The logic is straightforward: the LHRH agonist eliminates most testosterone, and bicalutamide mops up the small amount still produced by the adrenal glands.

A meta-analysis of more than 30 studies found that when a non-steroidal antiandrogen like bicalutamide was added to an LHRH agonist, the risk of death dropped compared to the LHRH agonist alone. One analysis reported a five-year survival rate of about 75% for the combination versus roughly 63% for the LHRH agonist by itself.² Another estimate put the reduction in all-cause mortality at around 20% when bicalutamide 50 mg was added to castration-level therapy.³

Preventing the Testosterone Flare

There is a second reason bicalutamide is often started a few weeks before an LHRH agonist. When you first begin an LHRH agonist, there is a temporary surge in testosterone before levels eventually crash. This surge, sometimes called a “flare,” can briefly worsen symptoms in men whose cancer has already spread, potentially causing bone pain or urinary obstruction. Because bicalutamide blocks the receptor, it shields the cancer cells from that testosterone spike. Randomized trials have confirmed that adding an antiandrogen reduces the incidence of flare-related problems.⁴ Bicalutamide can suppress the initial rise in PSA (a marker for prostate cancer activity) as effectively as older antiandrogens used for this purpose, though the suppression may take slightly longer to kick in.⁵

High-Dose Monotherapy

Outside the United States, bicalutamide has a second approved role at a higher dose of 150 mg per day, used on its own rather than in combination with testosterone-lowering drugs. In the European Union and other countries, this regimen is approved for men with locally advanced prostate cancer that has not yet spread to distant sites.⁶ The appeal of monotherapy is that it avoids the full hormonal castration that comes with LHRH agonists or surgical removal of the testes. Men on bicalutamide alone retain most of their testosterone, which can mean fewer problems with fatigue, hot flashes, and loss of sexual function.

Large trials found that bicalutamide 150 mg given immediately after diagnosis or treatment with curative intent significantly reduced the risk of disease progression compared to watchful waiting.⁷ Comparisons between the 150 mg monotherapy and full androgen blockade in locally advanced disease have shown broadly similar outcomes, reinforcing the idea that high-dose bicalutamide can serve as an alternative for men who want to preserve quality of life.⁸ This option is less commonly used in metastatic disease, where stronger suppression tends to be favored.

Why Once a Day Is Enough

Bicalutamide is a racemic drug, meaning each pill contains two mirror-image versions of the molecule. Only one version, the R-enantiomer, actually blocks the androgen receptor. The other, the S-enantiomer, clears from the body within hours and does essentially nothing.⁹ The active R-enantiomer, by contrast, hangs around for about a week in the bloodstream. That long half-life means a single daily pill builds up to steady, effective levels over the first few weeks, and missing a dose by a few hours is unlikely to cause a significant dip in drug exposure.¹⁰ The drug’s behavior in the body does not appear to change meaningfully in people with liver disease, based on pharmacokinetic studies comparing healthy subjects to those with impaired liver function.

Side Effects

Bicalutamide’s side-effect profile is shaped by how it blocks androgens. The most common and most discussed side effects are breast enlargement (gynecomastia) and breast tenderness. These occur because blocking androgen receptors shifts the hormonal balance in breast tissue, allowing estrogen-driven effects to dominate. At the 150 mg monotherapy dose, breast-related symptoms are extremely common. One placebo-controlled study found that nearly 97% of men on bicalutamide 150 mg experienced breast events when no preventive treatment was given.¹¹ At the 50 mg dose used in combination therapy, the rates are lower because testosterone itself is already suppressed, but the symptom is still recognized.

Managing Breast Side Effects

The breast symptoms are treatable. Tamoxifen, a drug better known for breast cancer prevention in women, has been studied specifically for this purpose. A dose-response trial found that tamoxifen at 20 mg per day reduced bicalutamide-induced breast events from about 97% down to roughly 9%.¹¹ Preventive radiation to the breast area has also been tested, though a head-to-head comparison found tamoxifen more effective: only about 8% of men on tamoxifen developed gynecomastia versus about a third of those who received radiation.¹²

Liver Safety

Liver function is the other area that requires monitoring. Mild, temporary elevations of liver enzymes show up in a proportion of patients and typically resolve on their own. Rarely, however, bicalutamide can cause severe liver damage. Case reports describe fulminant hepatotoxicity that, in the worst outcomes, can be fatal.¹³ For this reason, guidelines call for liver enzyme testing before starting the drug and periodic monitoring throughout treatment.¹⁴ Severe liver injury is rare enough that it has not limited the drug’s overall use, but the risk is not trivial enough to ignore.

Bone Health Compared to Castration

One often-overlooked advantage of bicalutamide, especially in monotherapy, relates to bone density. Testosterone and estrogen both help maintain bone strength, so treatments that suppress testosterone dramatically tend to weaken bones over time. A study comparing bicalutamide 150 mg monotherapy to leuprolide (an LHRH agonist) found a striking difference: lumbar spine bone mineral density dropped by about 2.5% in the leuprolide group over 12 months but increased by the same amount in the bicalutamide group.¹⁵ Differences at the hip and other skeletal sites were also significant. Because bicalutamide does not lower testosterone, the body still converts some testosterone to estrogen, which protects bone. For men already at risk of osteoporosis, this can be a meaningful consideration when weighing treatment options.

How It Compares to Other Antiandrogens

Bicalutamide was not the first non-steroidal antiandrogen. Flutamide came earlier, and nilutamide was also available. Bicalutamide gradually displaced both, largely because of tolerability and convenience. Compared to flutamide, bicalutamide causes significantly less diarrhea. A large double-blind trial comparing the two drugs alongside an LHRH agonist found that 26% of men on flutamide experienced diarrhea versus 12% on bicalutamide, and far more flutamide patients withdrew from treatment because of it.¹⁶ Compared to nilutamide, bicalutamide has fewer adverse effects overall. And the week-long half-life of its active component allows once-daily dosing, a practical advantage over flutamide’s three-times-daily schedule.¹⁷ Reviews of the evidence have characterized bicalutamide as having a more favorable side-effect profile, stronger receptor binding, and better evidence for survival benefit in at least one randomized trial compared to the older first-generation drugs.¹⁸

The Newer Generation

The landscape has shifted again with newer antiandrogens like enzalutamide (Xtandi), which was specifically designed to work in cancers that have become resistant to earlier therapies. In the STRIVE trial, which enrolled men with castration-resistant prostate cancer, enzalutamide reduced the risk of disease progression or death by 76% compared to bicalutamide. Median time without progression was about 19 months on enzalutamide versus under 6 months on bicalutamide.¹⁹ That gap reflects a real biological difference: enzalutamide binds the androgen receptor more tightly and also blocks the receptor from entering the cell nucleus and binding DNA, steps that bicalutamide does not fully prevent. Enzalutamide is more expensive and comes with its own side effects, including seizure risk in rare cases, so bicalutamide has not vanished from practice. But in advanced castration-resistant disease, the newer agents have largely taken over first-line roles.

When Stopping the Drug Is Itself a Treatment

One of the more counterintuitive phenomena in prostate cancer is the antiandrogen withdrawal response. In some men whose cancer has progressed while on bicalutamide, simply stopping the drug leads to a drop in PSA and sometimes even improvement on imaging. This happens because the cancer’s androgen receptors can mutate over time in a way that turns bicalutamide from an antagonist into an unintentional activator. The receptor essentially learns to use the blocking drug as fuel. Case reports have documented dramatic responses after bicalutamide discontinuation, with sharp declines in PSA and visible shrinkage of disease.²⁰ This phenomenon is well enough recognized that oncologists routinely trial withdrawal before switching to a new therapy when PSA rises on bicalutamide.

Off-Label Uses Beyond Prostate Cancer

Because bicalutamide blocks androgen receptors throughout the body, not just in the prostate, clinicians have explored it for several conditions driven by androgen activity. These uses are off-label, meaning the drug is not formally approved for them, but published evidence supports the practice in certain settings.

Gender-Affirming Hormone Therapy

Transgender women and some nonbinary people seeking feminization sometimes use bicalutamide as part of their hormone regimen. It blocks testosterone’s effects on skin, hair, and body composition without lowering testosterone levels themselves, which some patients and providers see as an advantage over other anti-androgens that carry different side-effect burdens. Published data on bicalutamide in this population remain limited, and there is ongoing interest in building a stronger evidence base for its efficacy and safety in transgender adults.²¹ The same liver-monitoring precautions apply.

Hirsutism in Polycystic Ovary Syndrome

Women with polycystic ovary syndrome (PCOS) often deal with excess facial and body hair driven by elevated androgens. A randomized controlled trial tested bicalutamide combined with an oral contraceptive pill against the contraceptive alone in women with severe hirsutism. The bicalutamide group had a greater reduction in hair growth, with no serious adverse effects beyond an increase in cholesterol markers.²² Bicalutamide is not a first-line treatment for hirsutism, but it represents an option when standard therapies fall short.

Familial Male-Limited Precocious Puberty

A rare genetic condition causes boys to enter puberty far too early, sometimes before age four, due to a mutation that makes the testes produce testosterone without the normal hormonal signal. Standard puberty-blocking drugs that work through the brain’s hormonal axis do not help because the problem sits downstream. Bicalutamide, paired with an aromatase inhibitor to prevent estrogen-driven bone maturation, has shown promise in case reports. In one case, a boy treated with bicalutamide and anastrozole showed regression of secondary sexual characteristics and slowed bone age advancement despite persistently elevated testosterone.²³ Other case reports have described similar successes with no short-term side effects.²⁴ The combination is considered a reasonable treatment option for this rare condition, though long-term data are still being gathered.²⁵

Female Pattern Hair Loss

More recently, dermatologists have taken an interest in bicalutamide for androgenetic alopecia in women. Because the drug blocks androgen receptors in hair follicles, it may slow or reverse the miniaturization of hair that characterizes this type of hair loss. Published reviews note off-label use for improving hair-loss grading scales in female patients, though the evidence base remains early-stage and relies largely on case series rather than large controlled trials.

Practical Considerations for Patients

If you are starting bicalutamide, a few practical points are worth knowing. The drug is taken as a single tablet each day, with or without food. Because of its long half-life, blood levels build up over several weeks, so the full effect is not immediate. Your doctor will likely order liver function tests before the first dose and periodically after that. Most guidelines suggest checking at least within the first few months and again if you develop any symptoms like nausea, dark urine, or abdominal pain. If breast tenderness develops and bothers you, ask about prophylactic tamoxifen early rather than waiting, since prevention works better than treatment after the fact.

If you are on the 50 mg dose as part of combined androgen blockade and your PSA begins to rise, do not assume the drug has simply stopped working. The antiandrogen withdrawal response means your oncologist may recommend stopping bicalutamide first and watching whether PSA falls before switching to a different treatment. This observation period can last several weeks and sometimes avoids the need for an immediate change in therapy. It is a well-established clinical step, not a sign that something has been missed.